Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 08, 2023 | June 12, 2023 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.67 · Expires 2033-06-08 | Direct | 16,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.
Intellia Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,716 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 4,425 · Balance 11,716 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2033-06-13 | Direct | 6,473 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 6,473 · Balance 6,473 F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date January 09, 2024 · Filed March 15, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-03-15. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 927,013 |
Last balance in matching sequence
After 2024-01-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-01-09 · Grant · Acquired 57,620 · Balance 995,492 F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 2 · 2024-01-09 · Tax withholding · Disposed 36,865 · Balance 958,627 F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 3 · 2024-01-10 · Sale · Disposed 31,614 · Balance 927,013 F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2020 Filed Jun 18, 2020 00:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $10.88 | $217,610.00 |
DisclosureSEC source: 0001209191-20-037466 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.60 to $11.17 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-20-037466 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 4, 2020 01:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 9,755 | $12.66 | $123,452.45 |
DisclosureSEC source: 0001209191-20-034327 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,186 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $12.90 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2020 Filed Jun 4, 2020 01:14 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034327 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,941 F1 · kind: The gift of shares reported on this Form 4 were made to 501(c)(3) charities, including the Make-A-Wish Foundation of America. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:52 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-20-030741 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of May 15, 2020, 95,401 options were fully vested and exercisable and 47,084 remained unvested from this individual 2017 grant. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:52 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $11.44 | $228,796.00 |
DisclosureSEC source: 0001209191-20-030741 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,941 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.01 to $11.64 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:52 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-20-030741 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 5, 2020 21:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 9,755 | $11.32 | $110,468.55 |
DisclosureSEC source: 0001209191-20-027248 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,941 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.13 to $11.56 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 23:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-20-024983 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of April 15, 2020, 109,516 options were fully vested and exercisable and 52,969 remained unvested from this individual 2017 grant. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 23:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $9.92 | $198,412.00 |
DisclosureSEC source: 0001209191-20-024983 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 949,696 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.77 to $10.07 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 23:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-20-024983 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 40,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023439 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 949,696 F3 · security: Granted in the form of Restricted Stock Units for the achievement of the 2018 PRSU Revenue goal. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest on December 31, 2020, subject to the reporting person's continued service with the Company. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 22:43 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 9,755 | $9.08 | $88,607.59 |
DisclosureSEC source: 0001209191-20-023439 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909,081 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.74 to $9.59 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-20-021005 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of March 20, 2020, 123,631 options were fully vested and exercisable and 58,854 remained unvested from this individual 2017 grant. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $9.00 | $180,000.00 |
DisclosureSEC source: 0001209191-20-021005 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 22:40 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-20-021005 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:54 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 9,755 | $9.10 | $88,745.14 |
DisclosureSEC source: 0001209191-20-016349 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.78 to $9.33 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:44 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-20-011129 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of February 18, 2020, 137,746 options were fully vested and exercisable and 64,739 remained unvested from this individual 2017 grant. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:44 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $10.83 | $216,676.00 |
DisclosureSEC source: 0001209191-20-011129 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,591 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.74 to $10.92 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:44 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-20-011129 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 22:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 9,754 | $8.91 | $86,881.80 |
DisclosureSEC source: 0001209191-20-006478 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928,591 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.83 to $8.98 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 22:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 19,994 | $8.84 | $176,746.96 |
DisclosureSEC source: 0001209191-20-006478 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938,345 Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:37 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-20-004120 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of January 15, 2020, 151,861 options were fully vested and exercisable and 70,624 remained unvested from this individual 2017 grant. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:37 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 100,000 | $10.35 | $1,034,790.00 |
DisclosureSEC source: 0001209191-20-004120 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,339 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.90 to $10.54 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:37 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-20-004120 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2020 Filed Jan 15, 2020 01:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 64,264 | $9.46 | $607,937.44 |
DisclosureSEC source: 0001209191-20-003377 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,339 Read SEC document |
| January 10, 2020 Filed Jan 15, 2020 01:34 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 163,313 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-003377 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,603 F1 · price: Granted for the achievement of the 2017 PRSU TSR goal as determined by the Compensation Committee of the Board of Directors. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 01:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 19,994 | $9.18 | $183,544.92 |
DisclosureSEC source: 0001209191-20-002164 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 939,290 Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 403,409 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001209191-20-001202 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,409 Underlying: Common Stock · 403,409 shares Expires 2030-01-02 F3 · derivative.exercise_date: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 256,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-001202 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959,284 F1 · shares: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. F2 · price: The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2021. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:15 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Tax withholdingCommon Stock | 33,083 | $9.74 | $322,228.42 |
DisclosureSEC source: 0001209191-20-001202 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,611 Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 00:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-19-061199 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of December 16, 2019, 165,976 options were fully vested and exercisable and 76,509 remained unvested from this individual 2017 grant. Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 00:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $9.55 | $191,014.00 |
DisclosureSEC source: 0001209191-19-061199 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.46 to $9.66 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 00:42 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-19-061199 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-059112 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,439 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of December 2, 2019. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $10.38 | $207,618.00 |
DisclosureSEC source: 0001209191-19-059112 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.23 to $10.56 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-059112 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 22:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-058362 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,439 Underlying: Common Stock · 40,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of November 25, 2019. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 22:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 40,000 | $10.01 | $400,204.00 |
DisclosureSEC source: 0001209191-19-058362 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.05 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 22:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 40,000 | $3.82 | $152,800.00 |
DisclosureSEC source: 0001209191-19-058362 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 23:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-19-057311 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of November 15, 2019, 180,091 options were fully vested and exercisable and 82,394 remained unvested from this individual 2017 grant. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 23:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $9.52 | $190,390.00 |
DisclosureSEC source: 0001209191-19-057311 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.29 to $9.66 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 23:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-19-057311 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 22:50 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-19-056143 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,485 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of November 8, 2019, 200,091 options were fully vested and exercisable and 82,394 remained unvested from this individual 2017 grant. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 22:50 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $9.02 | $180,414.00 |
DisclosureSEC source: 0001209191-19-056143 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.00 to $9.06 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 22:50 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $5.13 | $102,600.00 |
DisclosureSEC source: 0001209191-19-056143 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 21:03 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 14,500 | $8.01 | $116,072.50 |
DisclosureSEC source: 0001209191-19-053182 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,694 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 21:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-19-049503 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,439 Underlying: Common Stock · 20,000 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options were fully vested and exercisable as of September 11, 2019. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 21:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 20,000 | $10.05 | $201,030.00 |
DisclosureSEC source: 0001209191-19-049503 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,194 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.145 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 21:09 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001209191-19-049503 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.